References
- Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al.. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802–8.
- Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros. 2012;11(6):461–79.
- Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, et al.. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32(5):356–66.
- Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ. 2007;335(7632):1255–9.
- Foundation CF. Patient registry 2011 annual report. Bethesda (MD): Cystic Fibrosis Foundation; 2011.
- Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother. 2006;58(4):822–9.
- Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis. 2005;52(2):123–7.
- Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998;27(1):23–7.
- Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al.. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis — the topic study: a randomised controlled trial. Lancet. 2005;365(9459):573–8.
- Riethmueller J, Ballmann M, Schroeter TW, Franke P, von Butler R, Claass A, et al.. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection. 2009;37(5):424–31.
- Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2012;(2):CD002009.
- Greenwood BC, Szumita PM, Lowry CM. Pharmacist-driven aminoglycoside quality improvement program. J Chemother. 2009;21(1):42–5.
- Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, et al.. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest. 1997;112(5):1208–13.
- Nicolau DP, Belliveau PP, Nightingale CH, Quintiliani R, Freeman CD. Implementation of a once-daily aminoglycoside program in a large community-teaching hospital. Hosp Pharm. 1995;30(8):674–6679–80.
- Hayes D Jr, Feola DJ, Murphy BS, Kuhn RJ, Davis GA. Eradication of pseudomonas aeruginosa in an adult patient with cystic fibrosis. Am J Health Syst Pharm. 2011;68(4):319–22.
- Prescott WA Jr, Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy. 2010;30(1):95–108.
- Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of pseudomonas aeruginosa infections. Clin Infect Dis. 2005;40(Suppl 2):S99–104.
- Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010;65(7):654–8.
- Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986;5(4):319–24.
- Kashuba AD, Bertino JS Jr, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother. 1998;42(7):1842–4.
- McNamara DR, Nafziger AN, Menhinick AM, Bertino JS Jr. A dose-ranging study of gentamicin pharmacokinetics: Implications for extended interval aminoglycoside therapy. J Clin Pharmacol. 2001;41(4):374–7.